OABI — OmniAb, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1846253 ·
Last close
$4.61
Market Cap
$670.25M
52W High
$5.43
52W Low
$1.30
ADV30
2,159,417
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 13,415,000 | 12,805,000 | -6,637,000 | -5,859,000 | 290,257,000 | 24,336,000 | 29,983,000 |
| Mar 2026 | 14,427,000 | 14,412,000 | -7,829,000 | -7,707,000 | 293,650,000 | 29,046,000 | 31,004,000 |
| Dec 2025 | 8,376,000 | 8,367,000 | -15,766,000 | -14,179,000 | 300,914,000 | 25,524,000 | 33,887,000 |
| Sep 2025 | 2,239,000 | 2,210,000 | -18,140,000 | -16,525,000 | 309,690,000 | 28,537,000 | 32,246,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,672,000
Investing CF
$-4,140,000
Financing CF
$27,867,000
CapEx
$-468,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.36
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-179,745,000
Inventory
$1,013,000
Receivables
$10,328,000
ST Investments
$27,659,000
EBIT TTM
$-48,372,000
Pretax Income TTM
$-45,709,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$38,457,000
EBITDA
$-21,596,000
Free Cash Flow
$-285,000
Enterprise Value
$558,656,896
Total Cash
$51,995,000
Total Debt
$18,913,000
Shares Out
145,390,398
Trailing EPS
$-0.36
Book Value
$1.79
ROE
-17.0%
ROA
-8.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 18,666,000 | -68,969,000 | -64,779,000 | 300,914,000 | 33,887,000 | 267,027,000 | -36,455,000 |
| Dec 2024 | 26,391,000 | -74,502,000 | -62,033,000 | 325,558,000 | 37,940,000 | 287,618,000 | -39,664,000 |
| Dec 2023 | 34,164,000 | -69,419,000 | -50,619,000 | 375,225,000 | 60,640,000 | 314,585,000 | 2,347,000 |
| Dec 2022 | 59,077,000 | -26,648,000 | -22,334,000 | 421,212,000 | 79,839,000 | 341,373,000 | -3,587,000 |
TTM Snapshot
Revenues TTM
$24,155,000
NetIncome TTM
$-60,165,000
OpCashFlow TTM
$0
Assets (Latest)
$300,914,000
Forward EPS
$-0.29
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $4.74 · call oi: 3,716 · put oi: 30
Expected Move to 2027-01-15:
±$2.62
(55.38%) —
implied range
$2.11 –
$7.36
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QDEL | QuidelOrtho Corp | $750.22M | $10.94 | — |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $775.88M | $7.54 | — |
| TKNO | Alpha Teknova, Inc. | $500.91M | $9.33 | — |
| NRC | NRC HEALTH | $432.88M | $19.57 | — |
| MYGN | MYRIAD GENETICS INC | $398.86M | $4.17 | — |
News headlines (Yahoo Finance, 1h cache)
OmniAb to Participate in Upcoming Investor Conferences
2026-08-26 12:00 · Yahoo
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook
2026-08-17 20:47 · Yahoo
Top Midday Gainers
2026-08-17 17:40 · Yahoo
OmniAb lifts 2026 cash outlook following licensing momentum
2026-08-17 11:01 · Yahoo
OmniAb Raises 2026 Financial Guidance
2026-08-17 10:06 · Yahoo
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
2026-08-17 10:01 · Yahoo
OmniAb (OABI) Q2 2026 Earnings Call Transcript
2026-08-14 10:58 · Yahoo
OmniAb Q2 Earnings Call Highlights
2026-08-07 06:04 · Yahoo
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 23:10 · Yahoo
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
2026-07-27 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.